Durham, NC (February 4, 2021) - Alessio Cortellini, M.D., was awarded The Oncologist's 3rd Annual Young Investigator Award for his research on evaluating the risk of immunotherapy treatment to patients with pre-existing autoimmune disease. The Oncologist journal established this award to foster advancements in the field of oncology by honoring a young researcher who is principal author of a high-impact article with the greatest potential to improve patient outcomes.
In his winning paper, Dr. Cortellini and his team provided a clear estimation of the increased risk of developing immune-related adverse events overall, and of relapsing of the underlying immune disease for patients with both inactive and active autoimmune diseases receiving immune checkpoint inhibitors. These findings should allow clinicians to properly counsel their patients and deliver immunotherapy in a safer way.
"This fine article addresses a very important question for clinicians confronted with a patient needing checkpoint therapy, but worried about underlying autoimmune disease," said Bruce Chabner, MD, Editor-in-Chief of The Oncologist and Clinical Director Emeritus of the Massachusetts General Hospital Cancer Center. "This is very helpful information, and alerts us to the real risk entailed in this therapeutic situation."
Dr. Cortellini is currently a consultant medical oncologist and visiting researcher at Imperial College London. He is working within the early phase clinical trial unit, led by Dr. David Pinato. His aim is to build an expertise in immunotherapeutic agents, with different mechanisms of action and in the early phase of clinical development.
Learn more about Dr. Cortellini or read the winning paper Clinical Outcomes of Patients with Advanced Cancer and Pre Existing Autoimmune Diseases Treated with Anti-Programmed Death 1 Immunotherapy: A Real World Transverse Study.
About The Oncologist: Now in its 25th year, this internationally peer-reviewed journal focuses on clear and concise interpretation addressing the multimodality diagnosis, treatment, and quality of life of the cancer patient. Each issue is meant to impact the practice of oncology and to facilitate significant communication in the introduction of new medical treatments and technologies. The Oncologist is the official journal of the Society for Translational Oncology (STO).
About AlphaMed Press: Established in 1983, AlphaMed Press, with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. The Oncologist® is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS® is the world's first journal devoted to this fast-paced field of research. STEM CELLS Translational Medicine® (SCTM;) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.